Figure 3.

AptMincle^DRBL suppresses DSS-induced colitis through a dose-dependent inhibition of colonic inflammation

(A) Daily changes in disease activity score (DAI) over the onset of DSS-induced colitis. (B) MPO activity within colon. (C) Body weight percentage change at the end of the experiment. (D) Colon length and (E) terminal DAI measured at day 7 with relation to treatment groups with AptMincle^DRBL (0.35, 1, or 3.5 mg/kg) or AptMincle^RND (3.5 mg/kg). Immunoblot analysis of (F) Syk or (G) P65 phosphorylation of total colonic lysates. (H) Representative photographs of colons from mice (DSS + AptMincle^DRBL is 3.5 mg/kg group only). These data are presented as the mean ± SEM and were analyzed by a repeated measures ANOVA with Tukey’s post hoc test. Black asterisks indicate significance against sham group, while red asterisks indicate significance compared with DSS group: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Mice are a composite of 10-week-old mice, n = 4–12, with experiments performed on separate days.